Opsona Therapeutics appoints chief medical officer

Chief executive steps down for personal reasons

Opsona Therapeutics, based in Dublin, Ireland, has appointed Leon Hooftman as chief medical officer. Dr Hooftman was formerly CMO at Chroma Therapeutics (UK). Prior to this he was head of clinical development at Celltech (UK). Hooftman has also worked for Hoffmann La-Roche and Syntex.

Chief executive Dr Mark Heffernan has stepped down for personal reasons but will remain as a non-executive board member. Bernd Seizinger has been appointed executive chairman and will oversee the search for a new ceo and assume additional responsibilities for the company's operations during this period.

To further strengthen the executive management team, one of the company's founding scientists and directors, Professor Luke O'Neill will assume the additional role of chief scientific officer.

Opsona's vp of pharmaceutical development, Mary Reilly, has taken a broader role within the company as vice president of pharmaceutical development and operations.

You may also like

Research & Development

Opsona Therapeutics wins EC research grant of €5.9m

For the clinical development of lead drug candidate OPN-305
Research & Development

Jabil and Kymanox collaboration to deliver end-to-end development, regulatory and manufacturing solutions

Jabil and Kymanox are partnering to combine their regulatory, technical, and manufacturing expertise to help life science companies streamline development and bring complex therapies to market faster
Research & Development

Piramal Pharma Solutions formalises partnership with IntoCell

Piramal Pharma Solutions has joined forces with IntoCell to broaden its bioconjugates offering and support innovation in the field
Research & Development

Immunology CRO reports shift to autoimmunity projects

RoukenBio reports a sharp rise in autoimmunity drug development projects and an almost 50% decrease in immuno-oncology (I-O) studies, showcasing the shift in drug development trends
Research & Development

Merck partners with Promega to advance 3D cell drug discovery technologies

Partnership combines Merck’s chemistry and organoid expertise with Promega’s assay technologies
Manufacturing

Streamlining bioconjugation for next-generation ADC development

Abzena’s proprietary ThioBridge™ technology delivers precision, scalability, and enhanced stability for antibody-drug conjugates
Regulatory

TurboFil offers industry-leading glove testing systems

Partnership with RAVONA delivers precision and compliance in aseptic environments
Subscribe now